|Bid||40.00 x 3100|
|Ask||40.30 x 1200|
|Day's Range||39.70 - 40.32|
|52 Week Range||26.27 - 40.33|
|Beta (3Y Monthly)||0.89|
|PE Ratio (TTM)||33.62|
|Earnings Date||Jan 30, 2019 - Feb 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||43.80|
MARLBOROUGH, Mass. , Feb. 14, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 8 th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 ...
To receive further updates on this Boston Scientific (NYSE:BSX) trade as well as an alert when it's time to take profits, sign up for a risk-free trial of Strategic Trader today.We are opening a new bullish trade on Boston Scientific (NYSE:BSX). BSX is a medical device company that manufactures coronary stent systems, cancer treatment catheter systems, Parkinson's deep brain stimulation systems and more.Medical device companies, like BSX, have been steady performers on Wall Street since 2013 as an increasing number of Americans have gained insurance coverage and are now able to receive treatment for their health conditions.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Strong Earnings and New AcquisitionsBSX released its quarterly earnings numbers last week on Feb. 6, before market open, and thrilled investors by announcing revenue numbers that were in-line with expectations and by beating earnings expectations by $0.07 per share -- coming in at $2.56 billion and $0.27 per share, respectively.Medical device companies have been able to maintain their pricing power in negotiations with insurance companies. This is a trend that is likely to continue well into the future, so BSX could see strong revenue and earnings for years to come.BSX is also expanding the medical devices it manufactures, which could result in more sales. In November 2018, it announced it would acquire BTG plc., the surgical device manufacturer. BSX also just acquired Millipede, Inc., a company that developed technology for dealing with mitral regurgitation. Breaking Above $38The company's positive earnings announcement seems to have been the catalyst investors had been waiting for to break the stock out of the consolidation range it had been in since September 2018. The post-earnings breakout at $38 completed and confirmed a "broadening-wedge" bullish continuation pattern for the stock.Daily Chart of Boston Scientific (BSX) -- Chart Source: TradingViewWhereas it had served as resistance before earnings, we anticipate $38 is now going to serve as a strong support level moving forward. If it does, we can sell slightly out-of-the-money puts on the stock and keep our entire premium when they expire. That would give us the chance to roll out our puts and collect even more income.To find out which BSX puts we're selling -- and to get access to our full portfolio of income-generating trades -- consider signing up for risk-free trial subscription to Strategic Trader today. InvestorPlace advisers John Jagerson and S. Wade Hansen, both Chartered Market Technician (CMT) designees, are co-founders of LearningMarkets.com, as well as the co-editors of Strategic Trader.Follow our Facebook page to receive each Trade of the Day direct to your News Feed -- and join the conversation.Compare Brokers The post BSX is Breaking Out for the First Time Since September 2018 appeared first on InvestorPlace.
Boston Scientific's (BSX) closure of Millipede acquisition and its buyout agreement with BTG plc are major developments for the company.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Today we'll evaluate Boston Scientific Corporation (NYSE:BSX)Read More...
Boston Scientific Corp NYSE:BSXView full report here! Summary * Perception of the company's creditworthiness is neutral * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for BSX with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BSX. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding BSX totaled $15.35 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NeutralThe current level displays a neutral indicator. BSX credit default swap spreads are decreasing, indicating some improvement in the market's perception of the company's credit worthiness. Additionally, they are within the middle of the range set over the last three years.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Stocks finally found their ceiling, right where it would have been expected. The S&P 500's close of 2731.61 was down 0.22% from Tuesday's last trade, with the 200-day moving average line confirming its role as a technical problem.Video game companies led the drop. Electronic Arts (NASDAQ:EA) kicked off the meltdown, falling 13% in response to disappointing guidance. Shareholders applied the same doubt to rivals Activision Blizzard (NASDAQ:ATVI) and Take-Two Interactive Software (NASDAQ:TTWO), however, sending them 10% and 14% lower on Wednesday.Not every name ended yesterday in the red though. Snapchat parent Snap (NYSE:SNAP) jumped 22% on Wednesday after posting encouraging Q4 results and then being upgraded by a handful of analysts.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAll of those moves are far too volatile to chase, however. Instead, tamer stocks charts like those of FirstEnergy (NYSE:FE), Boston Scientific (NYSE:BSX) and Mondelez International (NASDAQ:MDLZ) are shaping up as better, more reliable prospects. Boston Scientific (BSX)During the latter third of last year, Boston Scientific shares broke above a long-standing trading range. Though impressive, it also appeared to be a setup for a major pullback. * The 9 Best Stocks to Invest In During a Manic Market We got that pullback, though not fully. Since the end of December, MDLZ has pushed its way back above that resistance line. With a tankful of momentum at its disposal, Boston Scientific could forge ahead to higher highs again. There's one ceiling that needs to be broken first, though it was cracked yesterday. Click to Enlarge • The long-standing trading range is plotted with white dashed lines on the weekly chart. The renewed break out of that range validates the first bullish wave.• The more immediate technical resistance lies at $38.60, where shares peaked three times in October and November. BSX closed above that level on Wednesday, but it's far from set in stone.• It's only a fairly recent development, but there's a large amount of volume behind the buying spree that took shape late last year. Mondelez International (MDLZ)Mondelez International shares have been a huge winner since late December, with last week's 6.6% serving as a big exclamation point. It would be easy to be lured into being a buyer. Given the scope of the move in the rearview mirror, it would be easy to excuse this week's breather.There may be more to this week's pause than just a chance for the rest of the market to catch up, however. A closer, bigger-picture look reveals this is where one would expect the gain to run out of gas and then pull back. Click to Enlarge • In a long-term, philosophical sense, MDLZ has been in the habit of back-and-forth action. It doesn't remain overbought or oversold for very long, and the current overbought condition isn't apt to last long either.• Bolstering the likelihood that a ceiling has already been hit is the fact that last week's and this week's highs around $48 are in line with one of the most frequently hit ceilings going all the way back to 2016.• In the near term, Mondelez shares have stalled at a resistance level that has now tagged the past three major peaks going back to September. That line is plotted in yellow on both stock charts. FirstEnergy (FE)Finally, FirstEnergy isn't in trouble yet. And, it may not slip into a downtrend -- the stock's still on the upper side of most of its key moving average lines.When taking a step back and looking at the chart's performance from a distance, however, it's difficult not to notice the current tide has shifted from last year's bullishness to brewing bearishness. Click to Enlarge • The clues are subtle, but they're there. Chief among them is the fact that the divergence of the moving average lines we saw early last year has turned into a convergence. FE has also made its first lower high in months.• In the weekly timeframe, the MACD lines have been bearish since October.• Though the tide may be modestly bearish, until FirstEnergy falls below and stays below the white 200-day moving average line, there's still hope for a rebound move.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * Are These 7 Dividend Aristocrats ETFs Fit for a King? * 7 of the Best Emerging Markets Stocks to Buy * 5 Gold Stocks That Should Glitter in 2019 Compare Brokers The post 3 Big Stock Charts for Thursday: FirstEnergy, Boston Scientific and Mondelez appeared first on InvestorPlace.
Stocks that moved substantially or traded heavily on Wednesday: Snap Inc., up $1.55 to $8.59 The social media company beat Wall Street forecasts on a surge in revenue that helped slash its quarterly loss ...
Boston Scientific stock approached a breakout Wednesday after the medical giant topped fourth-quarter earnings expectations, though 2019 and first-quarter earnings guidance lagged.
Boston Scientific (BSX) is leaving no stone unturned to strengthen its core businesses and invest in global markets, which accounted for the uptick in sales across all geographies.
Boston Scientific Corp. (BSX) reported fourth-quarter earnings before the opening bell on Wednesday. The company posted non-GAAP earnings of 39 cents per share, beating consensus estimates by 3 cents per share, and GAAP earnings of 27 cents per share, topping estimates by 7 cents. Warning! GuruFocus has detected 3 Warning Sign with TSX:OGC.
The stock market was modestly lower in morning trade Wednesday. Dow Jones stock Disney is nearing an entry, while IBD 50 stock Paycom surged higher.
MARLBOROUGH, Mass. (AP) _ Boston Scientific Corp. (BSX) on Wednesday reported fourth-quarter net income of $386 million, after reporting a loss in the same period a year earlier. On a per-share basis, the Marlborough, Massachusetts-based company said it had net income of 27 cents. The results exceeded Wall Street expectations.
Boston Scientific (BSX) delivered earnings and revenue surprises of 5.41% and 0.11%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Lockheed Martin Investment Management Co. disclosed last week that it unloaded almost all of its Apple stock and cut its holdings of Exxon by more than half.
Boston Scientific Corp. said Wednesday it had net income of $386 million, or 27 cents a share, in the fourth quarter, after a loss of $615 million, or 45 cents a share, in the year-earlier period. Adjusted per-share earnings came to 39 cents, ahead of the 36 cents FactSet consensus. Sales rose to $2.561 billion from $2.408 billion, ahead of the FactSet consensus of $2.558 billion. The company said it now expects full-year revenue growth of 7% to 9% and adjusted EPS of $1.53 to $1.58, compared with a FactSet consensus of $1.58. For the first quarter, it expects revenue growth of 6% to 7% and adjusted EPS of 35 cents to 36 cents, below the FactSet consensus of 37 cents. Shares were not yet active premarket, but have gained 41% in the last 12 months, while the S&P 500 has gained 1.6%.
MARLBOROUGH, Mass. , Feb. 6, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated sales of $2.561 billion during the fourth quarter of 2018. This represents growth of 6.3 percent on ...
Match Group, Chipotle Mexican Grill, GM and a slew of other top stocks tee up to report earnings Wednesday, with many eyeing buy points.
Abbott or Stryker: Which Is a Better Medtech Bet in This Month?(Continued from Prior Part)High-growth businessesOn its fourth-quarter earnings conference call, Abbott Laboratories (ABT) forecast that its Established Pharmaceuticals segment would